文献速递白血病

克拉屈滨联合低剂量阿糖胞苷与维奈克拉交替阿扎胞苷与维奈克拉治疗新诊断急性髓系白血病

Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.
PubMed 文献 · Am J Hematol · 2026-04-25

这项II期研究纳入190例老年或不适合强化疗的新诊断AML患者,中位年龄68岁,采用克拉屈滨+低剂量阿糖胞苷+维奈克拉交替阿扎胞苷+维奈克拉方案。总体CR/CRi率84%,MRD阴性CR/CRi率75%;中位OS 52个月,中位EFS 50个月,治疗安全,多数3-4级不良事件为感染并发症。

要点

  • 总体CR/CRi率84%,MRD阴性CR/CRi率75%,TP53野生型患者分别为91%和77%。
  • 中位OS 52个月,中位EFS 50个月;2年和5年OS率分别为60%和45%。
  • 4周和8周死亡率分别为1%和3%,治疗安全,多数3-4级不良事件为感染。

核心结论

  • 该交替方案在老年或不适合强化疗的新诊断AML患者中产生高缓解率并转化为有利生存结局。

研究设计与样本

  • II期研究,纳入190例老年或不适合强化疗的新诊断AML患者,中位年龄68岁(范围47-84岁),13%≥75岁。
  • 按ELN 2022分类,预后良好、中等、不良风险分别占16%、20%、64%。

主要发现

  • 总体CR/CRi率84%,MRD阴性CR/CRi率75%;TP53野生型患者分别为91%和77%。
  • 4周和8周死亡率分别为1%和3%;应答者中44%接受异基因造血干细胞移植。
  • 中位OS 52个月,中位EFS 50个月;2年和5年OS率分别为60%和45%,2年和5年EFS率分别为56%和43%。
  • 达到MRD阴性CR的患者中位OS未达到,2年OS率70%。
  • 诱导后中性粒细胞绝对计数恢复(>1×10^9/L)和血小板计数恢复(>100×10^9/L)的中位时间分别为27天和24天。

临床怎么用

  • 该方案可用于老年或不适合强化疗的新诊断AML患者,缓解率高且早期死亡率低。
  • 达MRD阴性CR者预后更优,2年OS率达70%。
  • 治疗安全,需关注感染并发症的防治。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venetoclax-based low-intensity regimens have improved the outcomes of older or unfit patients with acute myeloid leukemia (AML). This phase II study investigated the combination of cladribine plus low-dose cytarabine and venetoclax alternating with azacitidine plus venetoclax for older or unfit patients with newly diagnosed AML. A total of 190 patients were included; the median age was 68 years (range, 47-84 years; 13% ≥ 75 years). By the European LeukemiaNet 2022 classification, 16%, 20%, and 64% were stratified as favorable, intermediate, and adverse risk, respectively. The rates of complete remission (CR)/CR with incomplete blood count recovery (CRi) and minimal residual disease (MRD) negative CR/CRi were 84% and 75% overall and 91% and 77% among patients with TP53-wild type AML, respectively. The 4- and 8-week mortality rates were 1% and 3%, respectively. Among responders, 44% proceeded to allogeneic hematopoietic stem cell transplantation. The median overall survival (OS) and event free survival (EFS) were 52 and 50 months, respectively. The 2- and 5-year OS rates were 60% and 45%, respectively. The 2-and 5-year EFS rates were 56% and 43%, respectively. Patients achieving MRD-negative CR had a median OS not reached and a 2-year OS rate of 70%. The median time to absolute neutrophil count recovery (> 1 × 109/L) and platelet count recovery (> 100 × 109/L) after induction was 27 and 24 days, respectively. Overall, the treatment was safe and most grade 3 and 4 adverse events were infectious complications. The combination produced a high rate of remissions, translating into favorable outcomes for older patients with newly diagnosed AML. Trial Registration: ClinicalTrials.gov idetifier: NCT03586609.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Kadia TM, Bataller A, Bazinet A, et al. Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol. 2026. PMID: 42035228. doi:10.1002/ajh.70328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。